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Abstract
The stereochemical factors that influence the tendencies for sequence specific binding of
platinum antitumour drugs to DNA are examined. The NHs of the platinum-amine moiety
can form hydrogen bonds to the 06 of guanine or to a phosphate oxygen of DNA. Modelling
the stereochemistry of the NH atoms can lead to compounds with a strong preference for
forming one type of adduct with DNA.
Introduction
Anti-cancer compounds such as cis-[Pt(NH3)2CI2] (cis-DDP) and [Pt(en)CI2]
preferentially attack purine moieties in DNA [1], the most common point of attack being
the N7 of guanine [2]. The nature of the non-leaving groups, i.e. the amine ligands, plays
an important, but not completely defined role in the anti-cancer activity of the drug. The
requirement that at least one hydrogen be attached to each nitrogen for significant
anticancer activity [3] has led to the speculation that this NH group forms a hydrogen bond
to the 06 of guanine [4] or to a phosphate oxygen [5].
In DNA, cis-platinum compounds crosslink adjacent purine residues [2] in a Head-
to-Head (HH) conformation in which both the H8 atoms are on the same side of the
platinum coordination plane [6]. The bifunctional adducts fall into two classes: (i)
intrastrand, i. e. d(GpG) (60%), d(ApG) (25%) and d(GpNpG) (<10%) and (ii)
interstrand linking two guanines (<10%) [7].
There is also evidence that platinum compounds form monofunctional adducts with
DNA which are precursors of the bifunctional adducts. The factors that influence the
frequency of the monofunctional adducts will indirectly affect the frequency of the
bifunctional adducts. Also, the geometry of the monofunctional adduct may influence the
propensity for formation of a bifunctional adduct.
This article concentrates on the contribution of H-bonding to the preference of
platinum for particular bases and particular cross-links.
Stereochemical control in Pt-DNA monofunctional binding
Formation of the monofunctional adducts requires that one of the chloro groups of
cis-DDP be displaced. It is believed that, on entering the cell, cis-DDP is hydrolyzed,
resulting in replacement of one or both chloride ligands by water and/or hydroxyl ligands
[8].
Under neutral conditions, platinum binds to the N7 atom of guanine, the N7 and N1
atoms of adenine, and the N3 atom of cytosine. In DNA, atoms involved in base pairing, i.e.
N1 of adenine and N3 of cytosine, are less available for metal binding than N7 atoms of
guanine and adenine which are exposed in the major groove. When platinum binds to N7 of
guanine or adenine, it is forced into close proximity with the substituent in the 6-position
of the purine. In the case of guanine, this substituent is an O(carbonyl) atom and Pt-..O
contacts in the range 3.28-3.53 A are observed. In the case of adenine, the substituent is
an NH2 group (Figure 1). The interaction with the NH2 group is almost certainly more
destabilizing than that with the carbonyl oxygen and so contributes to the preference
Pt(ll) has for N7 of guanine over N7 of adenine. This preference in the binding of cis-DDP
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to DNA was proved by the observation that only monofunctional adducts with N7 of
guanine, and not N7 of adenine, are found on digestion of cis-DDP-treated DNA [9].
Figure 1. Diagram of cis-DDP coordinated to N7 of Adenine and Guanine in A-T and G-C
base pairs, respectively.
NHs
N N---..H 0 Mo
ADENINE THYMINE
Stereochemical control in Pt-DNA bifunctional binding.
While there is as yet no unequivocal evidence that bifunctional binding of cis-DDP
to adjacent purine bases is responsible for its cytotoxic activity, such interactions are
unquestionably those which occur most frequently between cis-DDP and DNA and have
consequently attracted the greatest amount of attention.
The major binding site was found to be adjacent guanine bases of one strand
[d(GpG)] with a smaller amount bound to the d(ApG) sequence [9, 10]. Binding to d(GpA)
sequences was not found, or occurred at very low frequency, in binding studies with DNA
[9, 10] and the trinucleotide d(GpApG) [11].
The lower preference for d(ApG) binding compared with d(GpG) binding is
understandable on the basis of the lower kinetic preference for binding to adenine
compared with guanine [12]. However, this does not explain why binding does not occur to
d(GpA) sequences. Dewan has pointed out that when cis.DDP binds to the central guanine
in a d(ApGpA) sequence of B-DNA, the distance from the Pt atom to the N7 of the adenine
on the 5’-side is "3 and the distance to the N7 of the adenine on the 3’-side is "5 A [13].
This observation is consistent with a kinetic preference for the formation of d(ApG)
adducts over d(GpA) adducts. However molecular mechanics analysis of monofunctional
binding performed by Hambley showed that these distances change considerably; those on
the 5’-side then range from 4.55 to 5.59 A and those on the 3’-side from 3.86 to 5.25 A.
In nearly all cases, the distances were similar, with that on the 5’-side generally slightly
longer than that on the 3’-side, which is the reverse of the situation seen in the idealized
models [14].
The interaction between a NH3 ligand and groups in the 6-position of the 3’-purine
was proposed to contribute significantly to the difference in the frequencies of occurrence
of the d(ApG) and d(GpA) adducts. Models of cis-DDP bound to d(GpG) sequences of A-DNA
showed that there is a hydrogen bond between one ammine ligand and 06 of the guanine in
3’-position and another between the other ammine and a terminal oxygen of the 5’-
phosphate group [15] (Figure 2). When bound to B-DNA, cis-DDP makes the former of
these hydrogen bonds with equal facility but the orientation of the sugar-phosphate
backbone is such that the second does not form. Rearrangement of the 5’-sugar ring from
C2’-endo to C3’-endo brings the phosphate group into a position where the hydrogen bond
can form, yielding a model similar to that seen previously for cis-DDP bound to A-DNA
[5]. NMR studies have shown that formation of cis-DDP adducts generally causes a change
in the sugar conformation from C2’-endo to C3’-endo [16]. The same interaction was
observed in models of bifunctional binding and in the crystal structures of cis-DDP bound
to d(pGpG) and d(CpGpG) [17].
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Figure 2. Diagram of [Pt(NH3)2{d(pGpG)}] showing the proximity of the ammine ligands
to 06 of guanine in 3’ position and to a terminal oxygen of the 5’-phosphate group
respectively.
5’ end
3’ end
When cis-DDP binds to the d(ApG) sequence the situation is very similar to that
described previously for cis-DDP bound to GpG sequences. In contrast when cis-DDP binds
to the d(GpA) sequence of A-DNA or modified B-DNA (C3’-endo conformation of the 5’
sugar), the hydrogen bond to the 5’-phosphate is observed as before. However, since the
purine on the 3’-side is now adenine, which has an NH2 group in the 6-position, no
hydrogen bond between this purine and an ammine is possible. Rather, there are repulsive
H...H contacts in the range 2.59-2.64 A. This could explain the difference in the
frequencies of occurrence of the d(ApG) and d(GpA) adducts.
The proposal that interactions between an ammine ligand and groups in the 6-
position of the 3’-purine influence binding specificity was tested by designing compounds
able to interact favourably with the -NH2 group of an adenine in the 3’-position. Such a
compound should be able to bind to d(GpA) sequences in preference to d(ApG) and d(GpG)
sequences. One of these compounds was 2($),S($)-dichloro-methioninemethylester-
sulfoxide-platinum(ll) in which the O-atom of the sulfoxide is correctly oriented to H-
bonding to the adenine NH2 group [18].
Modelling the stereochemistry of the NH atoms.
An approach to the design of compounds which should have a strong preference for
forming one type of adduct with DNA, is to model the stereochemistry of the N-H atoms of
the non-leaving amine ligands so that they could bind stereospecifically to DNA [19].
The cis-dichloro(ethylenediamine)platinum(ll) which has been extensively
studied for its close similarity to cis-DDP and because it can be conveniently radiolabeled
[9, 20] has a puckered chelate ring which can assume either , or 5 conformation. The rate
of :k-6 interconversion is, however, fast under normal conditions and the average situation
is that of a planar chelate ring with the two hydrogens at each aminic group equally
displaced above and below the coordination plane [21].
Structurally related to ethylenediamine is 1,2-diaminocyclohexane (DACH). The
organic chain bridging the two nitrogens has two chiral carbons and the DACH ligand exists
in three isomeric forms with the R,R, $,$, and R,S configurations at the asymmetric
centres. The puckering of the five-membered chelate ring is determined by the
configuration of the ligand; is 5 in the $,S/somer; Z, in the R,R isomer and both Z, and 5,
rapidly intemonverting, in the $,R isomer.
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Kidani and coworkers reported that platinum complexes with DACH had biological
activities depending upon the chirality of the diamine ligand. The R,R isomer was
apparently endowed with greater antitumour activity and was less mutagenic than the $,$
isomer [22].
The reaction of the sulphate form of each of these isomers with DNA was
characterized as a possible explanation for the apparent differences in antitumour activity
[23]. The spectrum of adducts produced was similar for each isomer and similar to that
reported for cis-DDP with adduction at d(GpG), d(ApG) and (dG)2. The kinetics of
formation of the various adducts was the same for each isomer; total platination of DNA
was complete in 15 min as were bifunctional adducts at d(GpG) and (dG)2. However,
rearrangement to bifunctional adducts took several hours in the case of adducts at d(ApG)
sequences. These results did not provide a reason for the different activities of the
isomers. It was suggested that the interaction of these adducts with metabolic processes
such as DNA repair might explain the observed differences.
A comparative study of three platinum complexes with chiral diamines [PtCI2(N-
N)] (N-N 1,2-diaminopropane, DAP; 2,3-diaminobutane, DAB; and 1,2-diamino-
cyclohexane, DACH) was also carried on [24, 25] (Figure 3).
Figure 3. Diagram of [PtCI2(DAP)], [PtCI2(DAB)] and [PtCI2(DACH)] complexes
showing the configuration of the asymmetric carbons and the puckering of the chelate
rings.
H H
H
[PtCI=(DACH)]
Cc.c
cRcl
Configuration
at carbon(s) R S S,R R,S
The biological tests, in vitro, revealed a marked difference among isomers. For
instance the mutagenic activity, which is strictly related to the interaction of the drug
with DNA, could be even ten times greater in one isomer with respect to the corresponding
enantiomer. In all cases examined the S,$ isomer was by far the most mutagenic indicating
that the different isomers give adducts with DNA which can be discriminated by the
enzymatic systems involved in mutagenesis. The most striking differences being observed
for the DAB complexes.
Molecular models indicate that the stereochemistry of the N-hydrogens in the S,S
isomer is such to favour O6-NH hydrogen bonding of the guanine in the 3’-position (a
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quasi-axial hydrogen on the same side of 06 with respect to the platinum coordination
plane). This interaction, together with the hydrogen bonding of the second ammine to the
5’-phosphate group is known to stabilize the bifunctional binding of cis-DDP to d(GpG)
and d(ApG) sequences, lit is to be noted that the DAB species can interconvert the and ,
conformation of the chelate ring, however the preference for the equatorial position of the
methyl substituents makes the conformation favoured when the configuration of the
asymmetric carbons is S and the, conformation favoured when the configurations of the
asymmetric carbons is R].
Stereochemical control in Pt-mononucleotide interaction.
The ability of platinum compounds with chiral diamines to bind stereospecifically
could also be proved in reactions with mono-nucleotides. In DNA cis-DDP cross-links
adjacent purine residues in a Head-to-Head (HH) conformation in which both the H8
atoms are on the same side of the platinum coordination plane. When the two nucleotide
moieties are not linked by a phosphodiester group, the purines can have orientations in
which the H8s are on opposite sides of the platinum coordination plane; this orientation is
designated Head-to-Tail (HT) [26]. Normally only HT complexes are detected in solution
and in most solid state crystallographic studies [27, 28]. The HH atropisomer, which is
the best model for intrastrand binding of cis-platinum compounds to DNA, is difficult to
isolate and has been found in only a few crystal structures of cis-[Pt(NH3)2(9-
ethylguanine)2]X2 [29].
A recent investigation of complexes of the type [Pt(5’GMP)2(R,S,S,R-Me2DAB)]
[Me2DAB N,N-dimethyl-2,3-diaminobutane and the configurations at the four
asymmetric centres are R, S, S, and R at N, C, C, and N, respectively] led to the first
evidence for the existence of a HH atropisomer in solution [30] (Figure 4). In addition,
the HH atropisomer was found to exist in equilibrium with two HT atropisomers, the
predominant HT having the conformation. This was the first determination of the
chirality of a HT species in solution; the AHT conformation had been found in all
documented solid state structures for 6-oxopurine nucleot(s)ide complexes with metal
centres [28, 31].
The favoured HT atropisomer could form two O6-NH H-bonds, the HH atropisomer
could form one O6-NH H-bond and the other HT atropisomer could not form any O6-NH H-
bond. Thus, O6-NH H-bond appeared to dominate the stereochemistry of these complexes.
For the complex with all asymmetric centres on Me2DAB inverted,
[Pt(5’GMP)2(S,R,R,S-Me2DAB)], the dominant atropisomer had the ,HT configuration.
This result demonstrated that the stereochemistry of the ammine ligand influences the
conformational equilibrium between atropisomers. The use of platinum(ll) complexes of
stereochemically controlling ligands shows promise for controlling DNA or RNA
conformations.
A similar investigation performed on the less symmetrical [Pt(5GMP)2
(S, R, R, R-Me2 DAB)] and [Pt(5’GMP)2 (S, S, S, R-M e2 DAB)] species has also
demonstrated that both O6-NH and ROPO3-NH H-bonds are important in determining the
atropisomer formed [32].
The 06 can participate in H-bonding only when the 06 and the NH are on the same
side of the coordination plane. When, instead, the H8 and the NH are on the same side, only
phosphate group H-bonding is possible since in the normal anti conformation of 5’GMP,
the phosphate group is close to H8 and, thus, NH. Because the sugar moiety is flexible and
there is relatively free rotation about the glycosyl bond, it is possible that a H-bond
between the phosphate group and the NH is formed also when the H8 and NH are on opposite
sides of the coordination plane. A quasi-equatorial NH was found to be particularly
suitable to donate a strong hydrogen bond to the phosphate.
On the basis of molecular mechanics calculations it has been hypothesized that a
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diaminedichloroplatinum(ll) complex having N-hydrogens lying in the platinum-
coordination plane would hydrogen bond preferentially phosphate groups of opposite
strands and bind interstrand in preference to intrastrand. Such a compound has been
designed and prepared, and the results of cross-linking, DNA unwinding, and enzymatic
digestion/HPLC studies of platinated DNA of one such compound, namely [PtCI2(HPIP)]
(HPIP 1,4-aza-cycloheptane), were consistent with the prediction [33].
Figure 4. Diagram of different atropisomers for [Pt(5’GMP)2(R,S,$,R-Me2DAB)]
o
AHT
o
1
o o! .,.O
O O
Stereochemical control in platinum complexes with trans geometry.
Trans-DDP reacts extensively with DNA [34], however is sterically restricted in
the type of intrastrand cross-links it can feasibly produce; that is, it is unable to cross-
link neighbouring bases in DNA. Such cross-links represent about 90% of the adducts
produced by cis-DDP.
After a 1-h incubation, 85% of trans-DDP binds to double-stranded DNA as
monofuncti0nal adducts of deoxyguanosine (dG) and only 10% of the platination results as
bifunctional adducts within the first few hours of reaction. These cross-links are between
two dGs. Rearrangement to bifunctional adducts was only 50% complete in 24 h and 80%
in 48 h [35]. A quantitation of the distribution of Pt in DNA modified at 1:100
Pt/nucleotide showed that dG-Pt-dC, dG-Pt-dG and dG-Pt-dA formed at approximately
50%, 40% and 10% of the bifunctional adducts, respectively. The equivalent values for
the bifunctional adducts formed in single stranded DNA were dG-Pt-dG, 60%; dG-Pt-dA,
35%; and dG-Pt-dC, 5% [36]. Because the dG-Pt-dC bifunctional adducts were more
316G. Natile MetalBasedDrugs
prevalent in double-stranded DNA (40%) than in single stranded DNA (5%), they may
derive from interstrand cross-links [37]. The remaining bifunctional adducts may derive
from intrastrand cross-links between two bases separated by one or more intermediate
bases. In general, much larger doses of tran$-DDP than cis-DDP are required to form an
equal number of platinum adducts on DNA [38].
More recently has been reported that the presence of a planar ligand, such as
pyridine, greatly enhances the cytotoxicity of the trans structure, such that cytotoxicity
is equivalent to that of the analogous cis-isomer and, indeed, ci$-DDP itself [39].
Intracellular uptake was found to be enhanced for pyridine complexes relative to ammine
complexes although binding to calf thymus DNA was significantly less for pyridine than
for the analogous ammine complexes [40].
Also substitution of iminoether for ammine in cis- and trans-DDP has been found
to reverse the biological activity of the cis- with respect to the trans-isomer (Figure 5).
The complex with trans geometry showed the greatest in vitro cytotoxicity against P388
leukemia cells and displayed a relevant antitumour activity on P388 and P388/DDP-
bearing mice [41].
Figure 5. Diagram of trans-and cis-[PtCI2{NH=C(OMe)Me}2] complexes
H H
Pt .CI
The trans-iminoether complexes are characterized by a remarkable inability to
give interstrand cross-links which, instead, are formed in the reaction of trans-DDP
with double stranded DNA [42]. Again hydrogen-bonding might play a key role. The N-
bound hydrogen of the iminoether ligand is shielded by the ketoether residue and certainly
is in an unfavourable position to hydrogen bond phosphodiester residues of opposite
strands, a type of interaction which appears to promote the interstrand cross-links
formation.
Conclusion
It appears that by varying the stereochemistry of the N-Hs and the H-bonding
ability of the non-leaving ligands, it is possible to determine the preference of platinum
complexes for forming one type of adduct. If one of these lesions were responsible for
antitumour activity, it could be possible to produce platinum drugs with the maximum
possible activity.
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